FDA Approves Companion Diagnostic for the Detection of BRCA1/2 Mutations in Ovarian Cancer (
- FLASCO
- March 10, 2015
- Drugs
FDA Approves Companion Diagnostic for the Detection of BRCA1/2 Mutations in Ovarian Cancer
The FDA approval of olaparib occurred concurrently with that of a companion diagnostic, BRACAnalysis CDx. This genetic test is designed to detect the presence of mutations in the BRCA genes in blood samples from patients with ovarian cancer. To read more click here.